Topline results from a pivotal phase 3, open-label extension study showcase the long-term safety and efficacy of olanzapine and samidorphan (Lybalvi) in patients with schizophrenia, schizophreniform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback